Without expected results, they suspend the research protocol they were carrying out in the Guadalajara Civil Hospital (HCG) Fray Antonio Alcalde about the Janssen laboratory’s vaccine against Human Immunodeficiency Virus (HIV) as people do not have a defense system that will prevent new cases.
The hospital was one of the application centers in the Metropolitan area of Guadalajara as well as Mérida, Yucatán and Mexico City, as well as in countries in North America, Latin America and Europe, including Canada, Argentina, Peru, United States, Brazil and Australia.
It might interest you → Hospital Civil de Oriente: Building “A” will begin operations in September, Alfaro announces
The pharmaceutical vaccine was tested on 3,900 people, of which 84 were from Jalisco.
The general director of the OPD, Civil Hospital, Jaime Andrade Villanueva, reported that an external analysis on the biological was presented by the Security Committee, showing not very encouraging results of protection.
“The results of the vaccine where it was shown that it does not prevent new cases, unfortunate not being able to have this. It seems to me that there are many efforts at the international level. Moderna’s own messenger RNA vaccine is being run to see the efficacy, but we need to continue researching to have a protective vaccine”.
Within the framework of the announcement of the scientific-academic program of the International Congress of Advances in Medicine (CIAM), edition 24, he indicated that the people who participated in the study do not run any risk to their health, they should only follow the antiretroviral treatment and the measures to prevent the transmission of the virus.
The Mosaic program was the first to reach phase three in a clinical trial.
The investigation was scheduled to end in the first two months of 2024, however, the decision was made to suspend the protocol and the study to avoid a “false sense of protection.”
We recommend you → Noncommunicable Diseases, the most catastrophic pandemic facing the Health System in Jalisco
The objective of the Mosaic program was to find a safe and effective vaccine for the prevention of HIV, the study was focused on cisgender men and transgender people.
